Skip to content

school of pharmacy research logo [View Image]

Neuropharmacology Lab

HIV and viral protein effects on the blood brain barrier.

McRae M.

Tissue Barriers, 2016 Jan; 4(1):e1143543.

The effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine model.

Ellis K, Marlin JW, Taylor TA, Fitting S, Hauser KF, Rice G, McRae M.

J Pharm Pharmacol, 2015 Feb; 67(2):178-88

Differential expression of the alternatively-spliced OPRM1 isoform MOR-1K in HIV-infected Subjects.

Dever, SM, Costin BN, Xu R, El-Hage N, Balinang J, Samoshkin A, O’Brien MA, McRae MP, Diatchenko L, Knapp PE, Hauser KF. 2013.

AIDS, 2014 Jan 2; 28(1):19-30.

Safety, Tolerability and Efficacy of KP-1461 as Monotherapy for 124 Days in Antiretroviral-Experienced, HIV-1-Infected Subjects.

Hicks C, Clay P, Redfield R, Lalezari J, Liporace R, Ramirez JM, Schneider S, Sension M, DeGruttola V, Hughes J, McRae MP, Laurent JP.

AIDS Research and Human Retroviruses, 2012 Jun 28.

Postpartum Pharmacokinetics of Peramivir in the Treatment of Influenza H1N1: A Case Report.

Clay PG, Adiga R, Taylor TAH, Alsup R, Gerk PM, McRae, MP.

Obstetrics & Gynecology, 2011 Aug; 118(2 Pt 2):463-7.

Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies: A Single Oral Dose Study in Non-HIV-Infected Adults, and a 14-Day Dose-Escalating Study in Highly Antiretroviral-Experienced HIV-Infected Adults.

Clay PG, McRae M, Laurent JP.

J Int Assoc Physicians AIDS Care, 2011 Jul-Aug; 10(4):232-8.

Plasma Bile Acid Concentrations in HIV Infected Subjects Taking Protease Inhibitor Therapy: Possible Implications for Hepatotoxicity.

McRae MP, Rezk, NL, Bridges, AS, Corbett, AH, Tien, HC, Brouwer, KLR, Kashuba, ADM.

Pharmacotherapy, 2010 Jan;30(1): 17-24. 

Pharmacokinetics of once-daily fosamprenavir 1400 mg plus atazanavir 400 mg without ritonavir in HIV negative subjects.

McRae MP, Clay PG, Anderson P, Glaros AG.

Pharmacotherapy, 2009 Aug;29(8):937-42.

“One Pill, Once Daily": What clinicians need to know about Atripla®.

Clay PG, Taylor TAH, Glaros A.G., McRae MP, Williams C, McCandless D and Oelklaus M.

Clinical Therapeutics and Risk Management, 2008, 4(2):291-302. 

Ritonavir, Saquinavir and Efavirenz, but not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes.

McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, Leake BF, Kim RB, Brouwer KLR, Kashuba ADM.

Journal of Pharmacology and Experimental Therapeutics, 2006, 318 (3): 1068-75.

Cytokine Regulation of P-Glycoprotein.

McRae MP, Brouwer KLR, Kashuba ADM.

Drug Metabolism Reviews, 2003, 35 (1): 19-33.

View graphic version